Regulatory Approvals

The drug works as a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist, requiring no food or water restrictions before taking it.

The collaboration targets two key challenges with MSD’s existing Zaire Ebola vaccine: complex manufacturing requirements and the need for ultra-cold storage.

Awiqli® changes that by offering a single weekly dose, giving patients greater flexibility to fit treatment into their individual lifestyles and preferences.

Avlayah’s approval validates Denali’s blood-brain barrier shuttle technology, which the company now applies across five clinical programs targeting Alzheimer’s disease, Parkinson’s disease, and Sanfilippo syndrome type A, among others.

The drug targets a specific immune deficit associated with bladder cancer, offering a mechanism distinct from conventional treatments.

GlobalData analysis projects that the global nephrology and urology device market, which includes BPH treatments, will reach almost USD12 billion in 2035, up from around USD8.6 billion in 2024.

The decision followed a comprehensive systematic review of published literature, which included case reports containing patient-level data and mechanistic studies that demonstrated the treatment’s potential benefits.

The expansion of Cosentyx to this population addresses a critical gap in care and demonstrates Novartis’ focus on advancing solutions where the company can make the greatest impact on patient outcomes.

The FDA based its approval decision on data from a global Phase IIIb clinical trial demonstrating Arexvy’s effectiveness in the younger adult population.

The recognition provides an important reference point for other countries working to strengthen their regulatory systems.